Uncategorized

Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics

Published

on

Eli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst cautioned, however, that the transaction should not be seen as “supporting a uniform re-rating of every psychedelic developer.”

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version